A long-acting insulin from Novo Nordisk was shown to have a greater risk of excessively lowering patients' blood sugar ...

Novo Nordisk is discontinuing one ... Luckily, there are many alternative insulins, both rapid-acting and long-acting. Zilbermint highlights Lantus (insulin glargine) as a good option.

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

intensifying the company’s race with Novo Nordisk to develop longer-acting insulins. Lilly’s once-weekly insulin, efsitora alfa, reduced the A1C measure of blood sugar comparably to daily ...

Novo Nordisk has said that the introduction ... That suggests its top-selling insulin products like rapid-acting NovoRapid (insulin aspart), premix NovoMix (insulin aspart/insulin aspart protamine ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast. In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Amycretin has some intriguing results in obesity Amycretin, an experimental Novo Nordisk obesity pill that ... “Obviously GLP-1, specifically the longer-acting GLP-1s, have changed the field ...

intensifying the company's race with Novo Nordisk to develop longer-acting insulins. Lilly's once-weekly insulin, efsitora alfa, reduced the A1C measure of blood sugar comparably to daily basal ...